shiri keret

[Rohit Aggarwal @docrota]

Dear Friends - Please join Myositis Clinical trial Consortium (MCTC) if you are interested in Myositis! Take a quick survey to be part of MCTC and collaborate in myositis studies ! We have 10 exciting global myositis project coming up in 2025 !

[Rohit Aggarwal @docrota]

What predicts poor outcomes of ILD in Myositis associated ILD? checkout Shiri’s poster at #ACR2024 which showed that higher age, Pulm HTN, decline in FVC and worsening dyspnea are predictors of 5 year mortality in ILD associated with myositis.
https://t.co/gq2x2GZLhN

[Rohit Aggarwal @docrota]

Learn the importance of normal or low levels of CK in Myositis at #ACR2024 by Shiri Keret. Great study to highlight importance of low CK levels in Myositis is quite significant clinically. https://t.co/KDoXvCgHye

[Rohit Aggarwal @docrota]

Congratulations Shiri for teaching us about normal CK in Myositis at #ACR2024

[Rohit Aggarwal @docrota]

Thanks Irada (#UPMC medicine resident) and Shiri (scientist from Israel) for #ACR2024 and presenting on predictors of ILD outcomes

[shiri keret @shirikeret]

Grateful for this fruitful collaboration

[Rohit Aggarwal @docrota]

Our Pittsburgh Myositis Center’s MAD (Myositis Accelerated Discovery) group at #ACR2024

[Rohit Aggarwal @docrota]

My appeal to everyone interested in myositis to collaborate on the #Myositis Clinical Trial Consortium (MCTC)! 🌍 A global alliance advancing clinical trials in myositis & related ILD.
🤝 Learn more & join: https://t.co/JSPl7Xdfmz
📋 Membership form: https://t.co/FWnAQnowJZ